Predict your next investment

Vivebiotech company logo
HEALTHCARE | Biotechnology

See what CB Insights has to offer

Founded Year



Series A - II | Alive

Total Raised


Last Raised

$1.13M | 2 yrs ago

About Vivebiotech

VIVEbiotech is a GMP Contract Development and Manufacturing Organization (CDMO) specialized in Lentiviral vectors. The company is focused on the manufacture of Research, Preclinical toxicology and GMP-grade lentiviral vectors.

Vivebiotech Headquarter Location

Mikeletegi Pasealekua 81

San Sebastian, 20009,


+34 943 308 568

Latest Vivebiotech News

VIVEbiotech Launches Lentiviral Vectors Mfg. Plant

Jun 4, 2021

Plant Increases production capacity by 400% to deliver commercial-size batches for Cell and Gene Therapy Sector. , a gene transfer technologies CDMO developing and manufacturing lentiviral vectors, is opening new facilities for the manufacture of lentiviral vectors for the cell and gene therapy sector. The facility will be capable of manufacturing batches ranging from those for early stage research to GMP for clinical and future commercial uses. The expanded facilities will allow the company to significantly increase its production capacity and deliver commercial-size batches of lentiviral vectors to both new and existing customers across the cell and gene therapy industry. VIVEbiotech’s production capacity will increase by 400%, with an increase in average batch size per year from 20 in 2020 to 80 in 2022. VIVEbiotech will also be able to broaden its product portfolio, and scale its delivery of products for all phases of clinical trial and commercialization. VIVEbiotech will install the largest bioreactor currently available on the global market, with seven cleanrooms set up specifically for lentiviral-vector manufacturing. Versatility in the design will result in a more flexible configuration enabling the possibility of further clean rooms in the future as well as making it feasible accommodating a much larger number of batches. VIVEbiotech has also expanded other key departments including R&D, upstream and downstream process development departments, and is expanding its workforce to 85 employees by the end of 2021. Kristin Brooks 06.02.21 Kristin Brooks 06.02.21 Kristin Brooks 06.02.21 Tim Wright, Editor, Contract Pharma 06.01.21 Tim Wright, Editor, Contract Pharma 06.01.21 Tim Wright, Editor, Contract Pharma 06.01.21 Kristin Brooks 05.28.21 Charles Sternberg, Assistant Editor 05.26.21 Kristin Brooks 05.26.21 Kristin Brooks 05.24.21 Kristin Brooks 05.24.21 Kristin Brooks 05.24.21 Tim Wright, Editor, Contract Pharma 05.21.21 Kristin Brooks 05.20.21 Kristin Brooks 05.20.21

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Vivebiotech

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Vivebiotech is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

5,239 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.